Life science startup Laverock Therapeutics has extended it seed round to more than £20m with additional backing from new and existing investors.
The company, which uses gene control technology to support the development of disease-responsive advanced therapies, raised £13.5m in 2023 seed round.
The seed extension investment follows the successful development of the company’s platform.
“The Laverock team has been busy over recent months, continuing to validate our technology platforms but also generating functional data for our therapeutic programmes,” said chief executive David Venables.
“This new funding will enable us to continue this development, as well as forming partnerships and collaborations to integrate our technologies into partners’ therapeutic pipelines. I’d like to thank all our existing and new investors for their continued support.”
New investor Calculus Capital led the extension round, with participation from Norcliffe Capital and existing investors Eli Lilly and Company, Mercia Ventures, Eos Advisory and Maven Capital Partners.
“We are delighted to continue our support for Laverock’s progress in pioneering a new era of
programmable advanced therapies,” said Calculus investment director Elizabeth Klein.
“This new data and expanded funding demonstrate the potential of Laverock’s technologies. We look forward to continuing our work with David and the team as they drive forward product development opportunities, as well as delivering value for our investors.”
Register for Free
Bookmark your favorite posts, get daily updates, and enjoy an ad-reduced experience.
Already have an account? Log in
